We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · November 29, 2021

SNO 2021: Apparent Benefits of Toca FC in Recurrent HGG Continue for an Average of 49.2 Months

The agent is an investigational nonlytic, retroviral-replicating vector.

PracticeUpdate Editorial Team

 

Further Reading